Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Xtampza ER — Product revenues, net

Other product segments

Belbuca
$57.67M+9.6%
Jornay PM
$46.06M+41.2%
Nucynta ER
$15.72M-21.2%
Symproic and other
$14.45M—
Nucynta IR
$14.36M-45.8%
Azstarys
$12.91M—
Symproic
$3.02M-18.9%
Nucynta ER AG
$2.78M—
Nucynta IR AG
$2.36M—

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$3.33B+13.2%
Vertex Pharmaceuticals logo
VRTXOther CF product revenues — Product revenues, net
$135.9M-12.5%
Vertex Pharmaceuticals logo
VRTXOther revenues — Product revenues, net
$0-100%
Vertex Pharmaceuticals logo
VRTXALYFTREK — Product revenues, net
$573.6M+266%
Vertex Pharmaceuticals logo
VRTXCASGEVY — Product revenues, net
$76.4M+151%
Vertex Pharmaceuticals logo
VRTXJOURNAVX — Product revenues, net
$49.6M+313%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$944.15M-1.3%
Enterprise value$798.74M-3.1%
P/E19.7×-6.7×
P/S1.2×-0.2×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Belbuca$57,669$52,600$110,318$104,258
Xtampza ER45,00652,60595,775100,247
Jornay PM46,05832,62684,95161,165
Nucynta IR14,35626,50140,43453,918
Nucynta ER15,72319,94633,95739,632
Azstarys12,910—12,910—
Symproic3,0203,7227,2136,537
Nucynta ER AG2,775—4,221—

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s xtampza ER — product revenues, net?
Collegium Pharmaceutical, Inc. (COLL) reported xtampza ER — product revenues, net of $45.01M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s xtampza ER — product revenues, net changed year-over-year?
Collegium Pharmaceutical, Inc.'s xtampza ER — product revenues, net decreased by 14.4% year-over-year, from $52.61M to $45.01M.
What does xtampza ER — product revenues, net mean?
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product after accounting for returns, discounts, rebates, and other sales allowances. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line financial performance. Tracking this figure allows investors to evaluate the growth trajectory and competitive positioning of the specific therapeutic asset within its respective market segment.

Ask your AI about Collegium Pharmaceutical, Inc.'s xtampza er — product revenues, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude